** Shares of medtech firm Senseonics Holdings rise 12.7% to 44 cents

** Co and Ascensia Diabetes Care announce that the U.S. FDA has cleared its continuous glucose monitoring system (CGM) called Eversense 365, that can be worn for one year

** The CGM is for people with Type 1 and Type 2 diabetes aged 18 years and older

** The device has a sensor that can be worn for a year, compared to every 10-14 days with short-term CGM systems, co says

** Expects to initiate the US launch of Eversense 365 US in the fourth quarter of 2024

** Including session moves, stock down 23.9% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))